Lung-selective 25-hydroxycholesterol nanotherapeutics as a suppressor of COVID-19-associated cytokine storm
- Authors
- Kim, H.; Lee, H.S.; Ahn, J.H.; Hong, K.S.; Jang, J.G.; An, J.; Mun, Y.-H.; Yoo, S.-Y.; Choi, Y.J.; Yun, M.-Y.; Song, G.Y.; Joo, J.; Na, D.H.; Kim, H.N.; Park, H.H.; Lee, J.-Y.; Lee, W.
- Issue Date
- Jun-2021
- Publisher
- Elsevier B.V.
- Keywords
- 25-hydroxycholesterol; Didodecyldimethylammonium bromide; Lung-selective nanohybrids; Sepsis; Severe COVID-19
- Citation
- Nano Today, v.38
- Journal Title
- Nano Today
- Volume
- 38
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/53999
- DOI
- 10.1016/j.nantod.2021.101149
- ISSN
- 1748-0132
1878-044X
- Abstract
- In response to the coronavirus disease-19 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), global efforts are focused on the development of new therapeutic interventions. For the treatment of COVID-19, selective lung-localizing strategies hold tremendous potential, as SARS-CoV-2 invades the lung via ACE2 receptors and causes severe pneumonia. Similarly, recent reports have shown the association of COVID-19 with decreased 25-hydroxycholesterol (25-HC) and increased cytokine levels. This mechanism, which involves the activation of inflammatory NF-κB- and SREBP2-mediated inflammasome signaling pathways, is believed to play a crucial role in COVID-19 pathogenesis, inducing acute respiratory distress syndrome (ARDS) and sepsis. To resolve those clinical conditions observed in severe SARS-CoV-2 patients, we report 25-HC and didodecyldimethylammonium bromide (DDAB) nanovesicles (25-HC@DDAB) as a COVID-19 drug candidate for the restoration of intracellular cholesterol level and suppression of cytokine storm. Our data demonstrate that 25-HC@DDAB can selectively accumulate the lung tissues and effectively downregulate NF-κB and SREBP2 signaling pathways in COVID-19 patient-derived PBMCs, reducing inflammatory cytokine levels. Altogether, our findings suggest that 25-HC@DDAB is a promising candidate for the treatment of symptoms associated with severe COVID-19 patients, such as decreased cholesterol level and cytokine storm. © 2021 The Author(s)
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/53999)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.